Drug Safety

Acknowledgement
pp. 1167-1169(3)
Author: Adis International Limited

Linking Pharmacovigilance with Pharmacogenetics
pp. 1171-1184(14)
Authors: David W.J. Clark; Emma Donnelly; David M. Coulter; Rebecca L. Roberts; Martin A. Kennedy

Benefit-Risk Assessment of the Levonorgestrel Intrauterine System in Contraception
pp. 1185-1204(20)
Author: Tiina Backman

Tolerability Profile of Metformin/Glibenclamide Combination Tablets (Glucovance®): A New Treatment for the Management of Type 2 Diabetes Mellitus
pp. 1205-1216(12)
Authors: Jaime A. Davidson; André J. Scheen; Harry C.S. Howlett

Tolerability of Treatments for Postherpetic Neuralgia
pp. 1217-1233(17)
Authors: Mark W. Douglas; Robert W. Johnson; Anthony L. Cunningham

Safety Issues Regarding Colonic Cleansing for Diagnostic and Surgical Procedures
pp. 1235-1242(8)
Authors: Larry E. Clark; Jack A. DiPalma

Drug-Induced Immune Thrombocytopenia
pp. 1243-1252(10)
Authors: Patricia M.L.A. van den Bemt; Ronald H.B. Meyboom; Antoine C.G. Egberts

An Algorithmic Computerised Order Entry Approach to Assist in the Prescribing of New Therapeutic Agents: Case Study of Activated Protein C at an Academic Medical Centre
pp. 1253-1261(9)
Authors: Michael A. Fischer; Craig M. Lilly; William W. Churchill; Lindsey R. Baden; Jerry Avorn